BR112017027762A2 - compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmos - Google Patents
compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmosInfo
- Publication number
- BR112017027762A2 BR112017027762A2 BR112017027762-0A BR112017027762A BR112017027762A2 BR 112017027762 A2 BR112017027762 A2 BR 112017027762A2 BR 112017027762 A BR112017027762 A BR 112017027762A BR 112017027762 A2 BR112017027762 A2 BR 112017027762A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- application
- aryl glycosides
- spirocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
a presente invenção fornece compostos de c,o-espiro aril glicosídeo, sua preparação e uso dos mesmos. são especialmente providos os compostos representados pela fórmula (i), em que as definições de cada grupo são descritas no relatório descritivo. os compostos podem ser usados como inibidores de sglt2 na preparação das composições farmacêuticas para o tratamento de doenças, tais como diabetes, aterosclerose, adiposidade e outros.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510353843.4A CN106317068A (zh) | 2015-06-23 | 2015-06-23 | 一种c,o-螺环芳基糖苷类化合物及其制备和应用 |
CN201510353843.4 | 2015-06-23 | ||
PCT/CN2016/086892 WO2016206604A1 (zh) | 2015-06-23 | 2016-06-23 | 一种c, o-螺环芳基糖苷类化合物及其制备和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017027762A2 true BR112017027762A2 (pt) | 2018-11-06 |
Family
ID=57584713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017027762-0A BR112017027762A2 (pt) | 2015-06-23 | 2016-06-23 | compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US10550143B2 (pt) |
EP (1) | EP3315502A4 (pt) |
JP (1) | JP6644814B2 (pt) |
KR (1) | KR102130155B1 (pt) |
CN (2) | CN106317068A (pt) |
AU (1) | AU2016282151B2 (pt) |
BR (1) | BR112017027762A2 (pt) |
CA (1) | CA3002878C (pt) |
HK (1) | HK1249898A1 (pt) |
RU (1) | RU2746858C2 (pt) |
WO (1) | WO2016206604A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112661736B (zh) * | 2021-01-12 | 2021-09-28 | 广州市力鑫药业有限公司 | 一种泰格列净中间体的合成方法 |
CN112645915B (zh) * | 2021-01-13 | 2021-10-08 | 广州安岩仁医药科技有限公司 | 一种sglt2抑制剂中间体的合成方法 |
CN113429379A (zh) * | 2021-06-28 | 2021-09-24 | 江苏法安德医药科技有限公司 | 一种lh-1801中间体及其制备方法和应用 |
CN115819398B (zh) * | 2022-10-31 | 2024-06-14 | 江苏联环药业股份有限公司 | 一类sglt2抑制剂关键中间体及其制备方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
UA90290C2 (ru) * | 2005-01-28 | 2010-04-26 | Чугаи Сейяку Кабусики Кайся | Производные спирокеталов и их применение в качестве лекарственного средства против диабета |
TW200637869A (en) * | 2005-01-28 | 2006-11-01 | Chugai Pharmaceutical Co Ltd | The spiroketal derivatives and the use as therapeutical agent for diabetes of the same |
JP5230613B2 (ja) * | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | グルコース輸送体阻害剤およびその使用方法 |
TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
CN101812043A (zh) * | 2009-02-19 | 2010-08-25 | 上海恒瑞医药有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
-
2015
- 2015-06-23 CN CN201510353843.4A patent/CN106317068A/zh active Pending
-
2016
- 2016-06-23 CN CN201680037415.3A patent/CN107709332B/zh active Active
- 2016-06-23 JP JP2017566825A patent/JP6644814B2/ja active Active
- 2016-06-23 WO PCT/CN2016/086892 patent/WO2016206604A1/zh active Application Filing
- 2016-06-23 CA CA3002878A patent/CA3002878C/en active Active
- 2016-06-23 US US15/738,675 patent/US10550143B2/en active Active
- 2016-06-23 RU RU2018102590A patent/RU2746858C2/ru active
- 2016-06-23 EP EP16813720.6A patent/EP3315502A4/en active Pending
- 2016-06-23 KR KR1020187002180A patent/KR102130155B1/ko active IP Right Grant
- 2016-06-23 BR BR112017027762-0A patent/BR112017027762A2/pt active Search and Examination
- 2016-06-23 AU AU2016282151A patent/AU2016282151B2/en not_active Ceased
-
2018
- 2018-07-17 HK HK18109276.6A patent/HK1249898A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3315502A4 (en) | 2019-03-20 |
AU2016282151B2 (en) | 2019-07-11 |
CA3002878C (en) | 2020-08-04 |
AU2016282151A1 (en) | 2018-02-15 |
CN106317068A (zh) | 2017-01-11 |
CN107709332A (zh) | 2018-02-16 |
EP3315502A1 (en) | 2018-05-02 |
KR102130155B1 (ko) | 2020-07-03 |
RU2746858C2 (ru) | 2021-04-21 |
CA3002878A1 (en) | 2016-12-29 |
RU2018102590A (ru) | 2019-07-23 |
JP6644814B2 (ja) | 2020-02-12 |
KR20180020276A (ko) | 2018-02-27 |
CN107709332B (zh) | 2019-12-20 |
WO2016206604A1 (zh) | 2016-12-29 |
US10550143B2 (en) | 2020-02-04 |
US20180305390A1 (en) | 2018-10-25 |
RU2018102590A3 (pt) | 2019-07-24 |
HK1249898A1 (zh) | 2018-11-16 |
JP2018520141A (ja) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018006448A2 (pt) | derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
BR112018007876A2 (pt) | derivado de benzofurano, método de preparação do mesmo e uso do mesmo na medicina | |
BR112017022604A2 (pt) | composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação | |
BR112016015706A8 (pt) | composto, uso do mesmo e composição farmacêutica | |
BR112018012756A2 (pt) | compostos heterocíclicos como imunomoduladores | |
BR112017005393A2 (pt) | composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição | |
BR112017003312A2 (pt) | compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
BR112018071408A2 (pt) | “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação | |
BR112018008397A2 (pt) | derivados de di-hidroimidazopirazinona úteis no tratamento do câncer | |
BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
ECSP15000868A (es) | Derivados de estra1,3,5(10),16tetraeno 3sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
BR112017012504A2 (pt) | derivados de piperidina como inibidores de hdac1/2 | |
BR112017003346A2 (pt) | derivados de pirazolopiridina, seus usos, e composição farmacêutica | |
DOP2014000059A (es) | Derivados de estra1,3,5(10),16tetraen3carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
BR112017027762A2 (pt) | compostos de c,o-espiro aril glicosídeo, preparação para os mesmos e uso dos mesmos | |
BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
BR112016030730A8 (pt) | composto | |
BR112018006545A2 (pt) | ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição? | |
CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
BR112017019750A2 (pt) | processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B11D | Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time |